Literature DB >> 29796737

Mefenamic Acid Attenuates Chronic Alcohol Induced Cognitive Impairment in Zebrafish: Possible Role of Cholinergic Pathway.

Venugopalan Rajesh1, Mohanan Mridhulmohan2, Subramanian Jayaseelan3, Palanivel Sivakumar4, Vellaiyachamy Ganesan5.   

Abstract

Based on the scientific evidence supporting the neuroinflammatory response contributes the cognitive impairment associated with chronic alcoholism and the neuroprotective actions of mefenamic acid with reversal of memory loss and brain inflammation in mice, this study was designed to evaluate the effect of mefenamic acid against chronic alcohol induced cognitive impairment in zebrafish model. Zebrafish were grouped and subjected to normal behavioral analysis in light-dark chamber for 10 days. The preference to dark compartment was noted in zebrafish. Zebrafish were grouped and exposed to escalating doses of alcohol for 28 days with and without mefenamic acid exposure (100 and 200 µg/L) and subjected to a fear conditioning passive avoidance task from day 13 of 28. The cognitive evaluation was performed for 10 days and the brain tissue was isolated to estimate acetylcholinesterase activity. In cognitive evaluation study, the normal zebrafish retained the memory of the learned task and avoided the dark. The alcohol exposed zebrafish showed impairment in retaining the memory of learned task. Mefenamic acid exposed zebrafish showed a significant protection against cognitive impairment caused by alcohol and retained the memory of learned task with a significant decrease in AChE activity in brain homogenate compared to alcohol exposed zebrafish. The results of this study suggest that the memory enhancing activity of mefenamic acid might be due to activation of cholinergic transmission that has protected neuroinflammatory and neurodegenerative conditions caused by alcohol.

Entities:  

Keywords:  Alcohol; Cognitive impairment; Fear conditioning; Light–dark chamber; Mefenamic acid; Zebrafish

Mesh:

Substances:

Year:  2018        PMID: 29796737     DOI: 10.1007/s11064-018-2554-3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  60 in total

Review 1.  The zebrafish as a model visual system.

Authors:  J Bilotta; S Saszik
Journal:  Int J Dev Neurosci       Date:  2001-11       Impact factor: 2.457

Review 2.  Vagus nerve stimulation therapy: a research update.

Authors:  Mark S George; Z Nahas; D E Bohning; F A Kozel; B Anderson; J-H Chae; M Lomarev; S Denslow; X Li; C Mu
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

3.  Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!

Authors:  N Tabet
Journal:  Age Ageing       Date:  2006-07       Impact factor: 10.668

4.  Evidence for neuroprotection by the fenamate NSAID, mefenamic acid.

Authors:  Parto S Khansari; Robert F Halliwell
Journal:  Neurochem Int       Date:  2009-06-27       Impact factor: 3.921

Review 5.  Role of hippocampus in alcohol-induced memory impairment: implications from behavioral and immediate early gene studies.

Authors:  A E Ryabinin
Journal:  Psychopharmacology (Berl)       Date:  1998-09       Impact factor: 4.530

6.  Ethanol effects on three strains of zebrafish: model system for genetic investigations.

Authors:  Cynthia A Dlugos; Richard A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2003-01       Impact factor: 3.533

7.  Mechanisms of statin-mediated inhibition of small G-protein function.

Authors:  Andrew Cordle; Jessica Koenigsknecht-Talboo; Brandy Wilkinson; Allison Limpert; Gary Landreth
Journal:  J Biol Chem       Date:  2005-08-04       Impact factor: 5.157

8.  Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?

Authors:  Bruno P Imbimbo; Vincenzo Solfrizzi; Francesco Panza
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

9.  Cognition Enhancing Activity of Sulforaphane Against Scopolamine Induced Cognitive Impairment in Zebra Fish (Danio rerio).

Authors:  Venugopalan Rajesh; Sakthivel Ilanthalir
Journal:  Neurochem Res       Date:  2016-06-02       Impact factor: 3.996

Review 10.  Alcohol-related dementia: an update of the evidence.

Authors:  Nicole J Ridley; Brian Draper; Adrienne Withall
Journal:  Alzheimers Res Ther       Date:  2013-01-25       Impact factor: 6.982

View more
  2 in total

1.  Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy.

Authors:  Valery Melnikov; Daniel Tiburcio-Jimenez; Martha A Mendoza-Hernandez; Josuel Delgado-Enciso; Luis De-Leon-Zaragoza; Jose Guzman-Esquivel; Iram P Rodriguez-Sanchez; Margarita L Martinez-Fierro; Agustin Lara-Esqueda; Osiris G Delgado-Enciso; Ivan Jacinto-Cortes; Sergio A Zaizar-Fregoso; Brenda A Paz-Michel; Efren Murillo-Zamora; Ivan Delgado-Enciso; Hector R Galvan-Salazar
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 2.  Fenamates as Potential Therapeutics for Neurodegenerative Disorders.

Authors:  Jaunetta Hill; Nasser H Zawia
Journal:  Cells       Date:  2021-03-22       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.